ISRCTN14732774
Completed
Not Applicable
Adoptive immunotherapy for adenovirus (AdV)-associated complications post transplantatio
Charité - University Medicine Berlin (Germany)0 sites306 target enrollmentStarted: March 31, 2006Last updated:
Overview
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Charité - University Medicine Berlin (Germany)
- Enrollment
- 306
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Pediatric patients, aged 2 to 18 years with:
- •1\. Acute leukemias (ALL)
- •2\. Acute myeloid leukemia (AML)
- •3\. Chronic myeloid leukemia (CML)
- •4\. Myelodysplastic syndromes (MDS)
Exclusion Criteria
- •1\. Patients in relapse or progress of AML or ALL and blast crisis of CML at the time of randomization
- •2\. All second transplants
- •3\. AdV seronegative recipients with seronegative matched related donors (MRD)
- •4\. Patients with severe non\-hematopoietic organ toxicity grade 3\-5 (according to the National Cancer Institute \[NCI] and Cancer Therapy Evaluation Program \[CTEP] reporting criteria) at the time of randomization
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Adoptive Immuntherapie der akuten ADV-Infektion nach allogener Knochenmark- oder peripherer Blutstammzelltransplantation - ÎAKSAdenovirus infection following allogeneic stem cell transplantation.EUCTR2005-001092-35-DE
Completed
Not Applicable
Oncolytic adenovirus therapy as an adjuvant treatment for localised prostate cancer.prostate cancerProstate carcinoma1003859710036958NL-OMON43563Erasmus MC, Universitair Medisch Centrum Rotterdam18
Not yet recruiting
Not Applicable
Oncolytic adenovirus therapy as an adjuvant treatment for localised prostate cancer.Oncolytic adenovirus therapy, Localised prostate cancer, Adjuvant treatment, Radical prostatectomyOncolytische adenovirus therapie, Gelokaliseerde prostaatkanker, Adjuvante behandeling, Radicale prostatectomieNL-OMON24928Erasmus MC18
Completed
Phase 1
Safety Study of ADV-specific T-cells in Paediatric Patients Post Allo-HSCTADV Infection Post Allo-HSCTNCT01822093Cell Medica Ltd8
Withdrawn
Phase 1
Virus-specific ImmunoTherapy Following Allogeneic Stem Cell TransplantationCytomegalovirus InfectionAdenovirus InfectionNCT02702427St. Anna Kinderkrebsforschung